INT240800

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 3
Disease Relevance 2.01
Pain Relevance 1.01

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Glp1r) signal transducer activity (Glp1r)
Anatomy Link Frequency
body 2
Glp1r (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Central nervous system 102 99.80 Very High Very High Very High
tolerance 54 99.62 Very High Very High Very High
antagonist 12 89.92 High High
amygdala 3 63.48 Quite High
Somatostatin 3 58.00 Quite High
Neuropeptide 9 5.00 Very Low Very Low Very Low
anesthesia 3 5.00 Very Low Very Low Very Low
Neurotransmitter 3 5.00 Very Low Very Low Very Low
Intracerebroventricular 3 5.00 Very Low Very Low Very Low
agonist 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Targeted Disruption 3 100.00 Very High Very High Very High
Impaired Glucose Tolerance 54 99.62 Very High Very High Very High
Aids-related Complex 159 92.88 High High
Diabetes Mellitus 6 90.00 High High
Appetite Loss 9 69.96 Quite High
Hyperinsulinism 9 61.52 Quite High
Hyperglycemia 9 60.84 Quite High
Hypoglycemia 3 32.44 Quite Low
Obesity 3 26.12 Quite Low
Stress 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Interestingly, the degree of impairment of glucose tolerance with CNS GLP-1 receptor antagonism was comparable with that seen in mice with a whole-body targeted disruption of the GLP-1 receptor (9).
Positive_regulation (targeted) of Gene_expression (disruption) of GLP-1 receptor in body associated with targeted disruption, tolerance, central nervous system and impaired glucose tolerance
1) Confidence 0.44 Published 2008 Journal Diabetes Section Body Doc Link PMC2494674 Disease Relevance 0.71 Pain Relevance 0.29
Further, since circulating GLP-1 is not increased during glucose tolerance tests, peripheral GLP-1 may not be the important source of GLP-1 activating the CNS receptors that regulate islet and hepatic function.
Positive_regulation (activating) of Gene_expression (source) of GLP-1 associated with tolerance, central nervous system and impaired glucose tolerance
2) Confidence 0.44 Published 2008 Journal Diabetes Section Body Doc Link PMC2494674 Disease Relevance 0.65 Pain Relevance 0.36
Further, since circulating GLP-1 is not increased during glucose tolerance tests, peripheral GLP-1 may not be the important source of GLP-1 activating the CNS receptors that regulate islet and hepatic function.
Positive_regulation (activating) of Gene_expression (source) of GLP-1 associated with tolerance, central nervous system and impaired glucose tolerance
3) Confidence 0.44 Published 2008 Journal Diabetes Section Body Doc Link PMC2494674 Disease Relevance 0.65 Pain Relevance 0.36

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox